Post-registration experience with divosilimab in patients with secondary progressive multiple sclerosis with recurrence
Abstract
Introduction . Therapy aimed at eliminating CD20-positive B cells is considered one of the most significant advances in the treatment of multiple sclerosis. Divozilimab is a humanized anti-CD20 monoclonal antibody lacking fucose in its Fc fragment, which enhances its effector properties. Aim . Тo analyze the efficacy and tolerability of divozilimab in patients with secondary progressive multiple sclerosis with exacerbations in real-world clinical practice. Materials and methods . The prospective observational study included 20 patients with secondary progressive multiple sclerosis with exacerbations (55% women, median age 53.5 years) who received divozilimab for 12–24 months. The annualized relapse rate, MRI activity (T1 gadolinium-enhancing lesions, new T2 lesions), EDSS dynamics, the proportion of patients achieving NEDA-3, safety profile, and lymphocyte levels were assessed. Results . Over 12 months, the annualized relapse rate decreased from 0.9 to 0.05 (p < 0.01); the proportion of relapse-free patients increased from 10% to 90%. At 12 months, 95% of patients had no gadolinium-enhancing lesions. The median EDSS remained stable at 4.0 points, with a tendency to decrease to 3.5 points at 24 months. NEDA-3 was achieved in 85% of patients. Infusion reactions were observed in 25% of patients (mostly mild, during the first administration). No serious adverse events were reported. Conclusion. Divozilimab demonstrates pronounced suppression of inflammatory activity and a favorable safety profile in patients with secondary progressive multiple sclerosis with exacerbations, justifying its use in this clinical population.